Susquehanna International Group’s Gyre Therapeutics GYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-35,912
| Closed | -$264K | – | 12997 |
|
|
2025
Q2 | $264K | Buy |
35,912
+18,981
| +112% | +$166K | ﹤0.01% | 10627 |
|
|
2025
Q1 | $131K | Buy |
+16,931
| New | +$186K | ﹤0.01% | 11330 |
|
|
2023
Q4 | – | Sell |
-2,823
| Closed | -$20.4K | – | 12723 |
|
|
2023
Q3 | $20.4K | Sell |
2,823
-847
| -23% | -$5.67K | ﹤0.01% | 11595 |
|
|
2023
Q2 | $19.4K | Sell |
3,670
-213
| -5% | -$764 | ﹤0.01% | 11644 |
|
|
2023
Q1 | $12.1K | Buy |
+3,883
| New | +$14.8K | ﹤0.01% | 12171 |
|
|
2022
Q3 | – | Sell |
-3,382
| Closed | -$42.9K | – | 13553 |
|
|
2022
Q2 | $45K | Sell |
3,382
-2,583
| -43% | -$17.2K | ﹤0.01% | 12038 |
|
|
2022
Q1 | $30K | Buy |
5,965
+508
| +9% | +$2.52K | ﹤0.01% | 12502 |
|
|
2021
Q4 | $38K | Buy |
+5,457
| New | +$93.3K | ﹤0.01% | 12677 |
|
|
2021
Q3 | – | Sell |
-7,363
| Closed | -$242K | – | 13051 |
|
|
2021
Q2 | $239K | Buy |
7,363
+2,692
| +58% | +$92.4K | ﹤0.01% | 11226 |
|
|
2021
Q1 | $177K | Buy |
4,671
+3,048
| +188% | +$139K | ﹤0.01% | 11521 |
|
|
2020
Q4 | $77K | Buy |
+1,623
| New | +$70.3K | ﹤0.01% | 10610 |
|
|
2020
Q3 | – | Sell |
-6,247
| Closed | -$244K | – | 10766 |
|
|
2020
Q2 | $275K | Buy |
6,247
+2,609
| +72% | +$123K | ﹤0.01% | 8501 |
|
|
2020
Q1 | $119K | Sell |
3,638
-2,509
| -41% | -$115K | ﹤0.01% | 9202 |
|
|
2019
Q4 | $314K | Buy |
6,147
+2,523
| +70% | +$106K | ﹤0.01% | 7924 |
|
|
2019
Q3 | $133K | Sell |
3,624
-6,589
| -65% | -$355K | ﹤0.01% | 9396 |
|
|
2019
Q2 | $565K | Buy |
+10,213
| New | +$638K | ﹤0.01% | 7033 |
|
|
2019
Q1 | – | Sell |
-2,083
| Closed | -$134K | – | 9233 |
|
|
2018
Q4 | $123K | Sell |
2,083
-14,212
| -87% | -$1.05M | ﹤0.01% | 8110 |
|
|
2018
Q3 | $1.32M | Buy |
16,295
+1,250
| +8% | +$99K | ﹤0.01% | 4716 |
|
|
2018
Q2 | $1.32M | Buy |
15,045
+2,848
| +23% | +$500K | ﹤0.01% | 4793 |
|
|
2018
Q1 | $2.36M | Buy |
+12,197
| New | +$2.28M | ﹤0.01% | 3614 |
|
|
2017
Q1 | – | Sell |
-209
| Closed | -$12.2K | – | 9322 |
|
|
2016
Q4 | $15K | Buy |
+209
| New | +$18.8K | ﹤0.01% | 9454 |
|
|
2014
Q4 | – | Sell |
-87
| Closed | -$168K | – | 9791 |
|
|
2014
Q3 | $173K | Buy |
87
+60
| +222% | +$148K | ﹤0.01% | 8793 |
|
|
2014
Q2 | $95K | Buy |
+27
| New | +$88.1K | ﹤0.01% | 9440 |
|
|
2014
Q1 | – | Sell |
-31
| Closed | -$115K | – | 9093 |
|
|
2013
Q4 | $102K | Buy |
+31
| New | +$122K | ﹤0.01% | 8628 |
|
|
2013
Q3 | – | Sell |
-149
| Closed | -$599K | – | 8535 |
|
|
2013
Q2 | $501K | Buy |
+149
| New | +$567K | ﹤0.01% | 6035 |
|
Other funds holding GYRE
SS
Susquehanna International Group's GYRE Position: Q3 2025 in Review
Susquehanna International Group sold out of Gyre Therapeutics (GYRE) in Q3 2025, closing a stake of 35,912 shares — an estimated $264K sold.
Susquehanna International Group first reported a position in GYRE in Q2 2013 and held it in 25 quarters. The position peaked at $2.36M in Q1 2018. 48 funds tracked by Wall St. Rank hold GYRE as of Q3 2025.
- Susquehanna International Group reported no remaining Gyre Therapeutics position as of Q3 2025 after selling out during the quarter.
- Susquehanna International Group sold 35,912 Gyre Therapeutics shares in Q3 2025, an estimated $264K.
- Susquehanna International Group first reported a position in Gyre Therapeutics in Q2 2013 and held it in 25 quarters.
- Susquehanna International Group's Gyre Therapeutics position peaked at $2.36M in Q1 2018.
- 48 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2025.
Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.